The Latest Cardiac and Vascular News
Dr. Arash Yavari Appointed to Chief Scientific Officer Hugo Fry Appointed to Chief Commercial Officer Komal Joshi Appointed to Chief Financial Officer BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced the appointments of Arash Yavari, M.B.B.S., DPhil., M.R.C.P., as […]
2021 total revenue was $43.2 million, including product sales of $40.1 million. Core non-COVID-19 product sales increased approximately 13% Y-Y to $33.8 million. 2022 marks the 10th anniversary of CytoSorb® commercialization MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care […]
Company joins Downtown North Urban Insight District in unique mixed-use space to accommodate growing surgical robotics business ST. LOUIS, March 09, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today is holding the grand opening of its new, 45,000-square-foot global […]
Dr. Egeland is a Founding Partner of Big Sky Biomedical and will transition from Advisor to Managing Director in his new role. MINNEAPOLIS (PRWEB) MARCH 07, 2022 Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing […]
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 8 March 2022, 7:00 am CET Ghent, Belgium, 8 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the […]
– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement Approval for CGuard from the French National Authority – – CGuard Included as Carotid Stent Treatment Option in National Institute […]
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data to Come from Cohort 5 of EnACT Trial – – Second in vivo Study of Oral LNC-remdesivir […]
– Reports Promising Early Data from Lead Clinical Program, JK07, for the Treatment of Heart Failure with Reduced Ejection Fraction – – Initiates Enrollment in Second Cohort of JK07 Phase 1 Dose Escalation Study – GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel […]
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. “CSI is developing an exciting product pipeline that targets some […]
SILVER SPRING, Md., March 03, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2021. […]
